Objective: The brain blood vessels of patients with type 2 diabetes and dementia have deposition of amylin, an amyloidogenic hormone cosecreted with insulin. It is not known whether vascular amylin deposition is a consequence or a trigger of vascular injury. We tested the hypothesis that the vascular amylin deposits cause endothelial dysfunction and microvascular injury and are modulated by amylin transport in the brain via plasma apolipoproteins. Methods: Rats overexpressing amyloidogenic (human) amylin in the pancreas (HIP rats) and amylin knockout (AKO) rats intravenously infused with aggregated amylin were used for in vivo phenotyping. We also carried out biochemical analyses of human brain tissues and studied the effects of the aggregated amylin on endothelial cells ex vivo. Results: Amylin deposition in brain blood vessels is associated with vessel wall disruption and abnormal surrounding neuropil in patients with type 2 diabetes and dementia, in HIP rats, and in AKO rats infused with aggregated amylin. HIP rats have brain microhemorrhages, white matter injury, and neurologic deficits. Vascular amylin deposition provokes loss of endothelial cell coverage and tight junctions. Intravenous infusion in AKO rats of human amylin, or combined human amylin and apolipoprotein E4, showed that amylin binds to plasma apolipoproteins. The intravenous infusion of apolipoprotein E4 exacerbated the brain accumulation of aggregated amylin and vascular pathology in HIP rats. Interpretation: These data identify vascular amylin deposition as a trigger of brain endothelial dysfunction that is modulated by plasma apolipoproteins and represents a potential therapeutic target in diabetes-associated dementia and stroke.
M icrovascular-related brain injury is associated with focal neurologic deficits and dementia. [1] [2] [3] [4] [5] The distal territories of small penetrating vessels (arterioles and capillaries) supplying brain white matter are particularly vulnerable to vascular pathologies (also known as cerebral small vessel disease). High blood pressure, atherosclerosis, and inflammation are among the major causes of brain white matter disease of vascular origin. [1] [2] [3] [4] [5] Recent investigations [6] [7] [8] have revealed that the brain microvasculature of patients with dementia contains large deposits of amylin, a 4kDa peptide cosynthesized with insulin by pancreatic b cells. 9 Vascular deposition of amylin is particularly abundant in the brains of patients with dementia and type 2 diabetes. 6, 7 The peptide amylin (or islet amyloid polypeptide) normally crosses the blood-brain barrier 10 and binds to neurons in the feeding centers, failing hearts 17, 18 and kidneys 19 of individuals with type 2 diabetes or obesity. Of note, apolipoprotein E4 (APOE4), which is strongly associated with b amyloid (Ab) pathology, 20, 21 modulates amylin aggregation 22 and amylin amyloid formation. 23, 24 Amylin from species that do not develop type 2 diabetes (ie, mice and rats) is nonamyloidogenic due to proline substitutions at the 25, 28, and 29 sites. 25 Pharmacological induction of insulin resistance in transgenic mice expressing the amyloidogenic amylin variant (i.e., human amylin) caused intra-and extracellular amylin amyloid deposition, b-cell apoptosis, and overt hyperglycemia. 26 Similar pathologic changes occur in rodents overexpressing human 27 but not murine amylin. 16 We previously reported that rats overexpressing human amylin in the pancreas accumulate aggregated amylin in the brain, 28 which correlates with the development of neuroinflammation, 28, 29 reduced synthesis (by >50%) of catecholamine precursors (phenylalanine and tyrosine), 30 and neurologic deficits. 28 Furthermore, a recent study demonstrated that transgenic mice overexpressing human amylin in pancreatic islets and a mutant form of the amyloid precursor protein in neurons have exacerbated Ab pathology compared to transgenic mice expressing only one or the other protein. 31 Distinct from other diabetic complications, glucose dysregulation does not appear to be the primary determinant of progressive brain injury in patients with diabetes. [32] [33] [34] [35] [36] [37] The pathophysiology underlying slowly progressive functional and structural brain changes in the setting of type 2 diabetes is largely unknown. [32] [33] [34] [35] [36] [37] Given the toxicity of aggregated amylin, 9, [15] [16] [17] [18] [19] we hypothesized that the complex pathophysiology [32] [33] [34] [35] [36] [37] underlying slowly progressive functional and structural brain changes in patients with type 2 diabetes involves accumulation of aggregated amylin in the brain blood vessels. Here, we tested the hypothesis that aggregated amylin circulates through the blood, deposits in brain blood vessels (possibly via the interaction with plasma apolipoproteins), and provokes brain microvascular injury by degrading endothelial cell coverage and tight junctions. To test this hypothesis, we performed in vivo phenotyping of rats expressing amyloidogenic (human) amylin in the pancreas (HIP rats 27 ) and generated amylin knockout (AKO) rats that were intravenously infused with aggregated human amylin. We also carried out biochemical analyses of brain tissues from humans and studied the effects of the aggregated amylin on endothelial cells, ex vivo. Our findings may contribute to the understanding of the complex molecular mechanisms underlying diabetesassociated stroke and dementia. [32] [33] [34] [35] [36] [37] 
Materials and Methods
This investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996) and was approved by the institutional animal care and use committees at University of Kentucky. Paraffin-embedded brain tissues were provided by the Alzheimer's Disease Center biobank at the University of Kentucky. The protocol was approved by the institutional review board.
For immunohistochemistry, formalin-fixed dorsolateral frontal cortex (Brodmann area 9) tissue was used from 3 autopsied individuals >80 years of age at death, with type 2 diabetes and dementia, and 3 age-matched cognitively normal individuals without type 2 diabetes (Supplementary Table) . The absence/presence of diabetes was determined during life (at longitudinal clinical visits) by patient or caregiver self-report and the use of diabetic medications. 38 The assessment of clinical dementia and the neuropathologic features-neuritic amyloid plaques (Consortium to Establish a Registry for Alzheimer's Disease [CERAD]), Braak NFT stage, and cerebral amyloid angiopathy (CAA) severity-were scored as previously described. [39] [40] [41] [42] [43] Neuropathological information, APOE genotype, age, and sex of each individual included in the present study are summarized with specific findings related to the vascular amylin pathology.
Experimental Animals
HIP rats (n 5 79; breeding pairs provided by Charles River Laboratories, Wilmington, MA) were used in behavior testing and physiological analyses. HIP rats are Sprague-Dawley rats that overexpress (3-fold) human amylin in the pancreatic b cells. 27 Wild-type (WT) littermate rats (n 5 49) were used as nondiabetic controls. AKO rats were used to identify a possible interaction of amylin with plasma apolipoproteins (APOE) and to test whether intravenous infusion of aggregated human amylin injures the brain microvessels independently of glucotoxicity. AKO rats (rather than WT rats) were used in amylin-injection experiments to eliminate the confound that rodent amylin and human amylin form mixed oligomers. 44 AKO rats were generated in collaboration with Transposagen Biopharmaceuticals (Lexington, KY). The rat amylin gene was targeted at 2 sites by producing double strand breaks in the genome using the CRISPR/Cas9 system. 45 The CRISPR gRNAs and Cas9 mRNA were microinjected into the pronucleus of fertilized Sprague-Dawley rat embryos by standard techniques, and the embryos were reimplanted to produce the genetically modified offspring. Amylin gene knockout was confirmed by genotyping using the following primers for DNA amplification: forward, 3 0 -AGAGCTAAGCAAGTTGAGGGAT-5 0 ; reverse, ACCAC TAGTTCACATTCACAGAGG. AKO rat pancreas was tested for amylin immunoreactivity signal by Western blot.
Behavior Testing INCLINED PLANE. Rats were placed on the flat plane in the horizontal position with head facing either up or down to the side to be raised. Starting at 308, the angle was increased at 28/ s. The angle at which the animal starts to free-fall was recorded. Each rat received 3 trials per head facing direction. Rats were allowed to rest 1 minute between trials. Results were averaged for 6 trials.
CYLINDER TEST/FORELIMB USE TEST. To evaluate forelimb deficits, the animal was placed in a transparent cylinder for 5 minutes, and the activity was video-recorded. The time that forepaws contacted the cylinder wall during vertical rearing up was calculated using slow-motion playback software (Kinovea).
MORRIS WATER MAZE. Visuospatial learning and memory retention was tested in a 1.5m diameter Morris water maze. 46 HIP and WT littermate rats with no motor impairments were given 10 learning trials per day for 2 consecutive days using random starting locations (north, east, south, west). Animals were allowed to stand on the platform for 30 seconds after the first trial and 15 seconds after each additional trial. If the animals failed to locate the platform, they were picked up and put on the platform for 15 seconds. To assess reference memory, a probe trial was given 24 hours after the second acquisition day. The probe trial was scored on latency to cross the platform. Trials were recorded by EthoVision XT software (Noldus, VA).
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) data were acquired using a horizontal 7T nuclear magnetic resonance scanner (ClinScan; Bruker BioSpin, Ettlingen, Germany) and a 38mm rat brain coil. Rats were first anesthetized with isoflurane (4.0% for induction, 1.2% for maintenance) and air mixture. Heart rate (90-130 beats per minute), respiration rate, and rectal temperature (37 6 0.58C) were continuously monitored. Heart rate and blood oxygen saturation level were maintained within normal physiological ranges. Coronal T 2 -weighted magnetic resonance images were obtained using the following variables: repetition time, 3,000 milliseconds; echo time, 24 milliseconds; field of view, 2.5 3 2.5cm 2 ; acquisition matrix, 128 3 128; thickness, 1mm, 7 slices. Ventricular volume was measured from the frontal horn of the lateral ventricle to the foramen of Luschka by combining hyperintense ventricular area using ImageJ over all slices and multiplying by section thickness. 47 Similarly, total brain volume was measured by multiplying combined brain area over all slices by section thickness. Parenchymal volume was calculated by subtracting ventricular volume from total brain volume.
Isolation of Rat Brain Capillaries
Freshly isolated brain was homogenized in capillary phosphatebuffered saline (cPBS; 137mM NaCl, 2. The capillaries were then isolated by the glass bead column filtration method. In the first step, the pellet resulting from the centrifugation was resuspended with 1% bovine serum albumin (BSA) in cPBS and passed through a 300lm strainer. Then, the filtered pellet suspension was added into the glass bead column. Two hundred milliliters of 1% BSA was passed through the column. Capillaries were retrieved from the beads by agitation in 1% BSA and filtering through a strainer, followed by centrifugation at 500 3 g for 5 minutes at 48C. Capillaries were washed twice with cPBS before the experiment. For quality control, capillaries were stained with Texas red dye and were examined under a confocal microscope.
Cerebral Blood Flow Measurement
Fluorescent microspheres (15lm diameter; F8839; Thermo Fisher Scientific, Waltham, MA) were vortexed for 30 seconds in heparinized saline (10 6 /ml fluorescent microspheres). Anesthetized HIP and WT rats were injected with a 200ll volume containing microspheres and heparinized saline through the jugular line twice (15 minutes apart). Animals were sacrificed, and the brains were collected for tissue digestion, capillary isolation (as described above), and microsphere recovery by filtration followed by fluorescence measurements.
Equal weights of brain capillaries and remaining parenchymal tissue from WT and HIP rats were individually digested in 4M KOH and 2% Tween 80 (Sigma-Aldrich, St Louis, MO). The tissue was completely digested within 24 hours. The digested tissue was then filtered through 10lm pore polycarbonate filters (Millipore, Billerica, MA). The vial and filtering syringe were washed twice with 2% Tween, and the wash was filtered to recover residual microspheres. The filter and filtered material from each tissue were placed in 1.25 ml of Cellosolve acetate (Sigma-Aldrich) in tubes. After 4 and up to 24 hours, 100ll samples from each tube were placed in a 96-well microplate and the florescence of each was determined by florescent spectrophotometer.
Histology
HIP, WT, and AKO rat brains were analyzed by staining with Prussian blue and Luxol fast blue (LFB). For Prussian blue staining, sections were microwaved in solution containing 5% HCl and 5% potassium ferrocyanide (14459-95-1; Acros Organics, Geel, Belgium). Nuclei were stained with neutral red (N7005, Sigma). For LFB staining, sections were treated with LFB (AC212170250, Acros Organics) solution overnight (O/ N) at 568C, followed by 95% ethanol and dH 2 O rinse. Slides were differentiated in lithium carbonate solution, then 70% ethanol, followed by hematoxylin and eosin (H&E) staining (BP2424-25, E511-100; Fisher Scientific, Pittsburgh, PA). Images were obtained on the Eclipse 55i upright microscope (Nikon, Tokyo, Japan).
Immunohistochemistry
We used brain tissues from humans and HIP, WT, and AKO rats. Tissues were processed as previously described. 6, 29 Antibodies against amylin (1:200, T-4157; Bachem-Peninsula Laboratories, San Carlos, CA), glial fibrillary acidic protein (GFAP; 1:600, MAB360, Millipore), and myelin basic protein (MBP; 1:5,000, AMAB91064, clone CL2829, Sigma) were the primary antibodies. Antimouse or antirabbit IgG (1:50, A3562, A3687, Sigma) were secondary antibodies. The specificity of the amylin antibody in both human and rat brain tissues was established in previous studies. 6, 7, 29 Demyelination Scoring
Demyelination of the white matter (MBP and LFB staining) was scored by a blinded observer. Ordinal pathologic scoring was used, ranging from normal to severe demyelination (0-3). 48 
Immunofluorescence
We used brain tissues from humans and HIP, WT, and AKO rats, and isolated brain capillaries from HIP, WT, and AKO rats. Brain tissue was processed as previously described. 29 Brain capillaries were isolated (as described above) and then plated on laminin ( 
Immunoprecipitation
HIP rat plasma was investigated in these experiments. Protein concentration was determined by bicinchoninic acid protein assay prior to immunoprecipitation. APOE was precipitated from 700lg plasma protein. Samples were incubated at 48C O/ N with 5lg anti-APOE antibody (ab183597, Abcam) or anti-APOA-1 antibody (H00000335-D01P; Abnova, Taipei, Taiwan). Antibody-antigen complex was precipitated out by protein A/G agarose (20421, Thermo Fisher Scientific), rotated for 3 hours at 48C. Immunoprecipitates were collected by centrifugation followed by washing 3 times with buffer (5mM ethyleneglycoltetraacetic acid [EGTA], 50mM Tris, 1% Triton X-100, phosphatase and protease inhibitors 1:100 ratio, pH 7.5). Proteins were eluted twice with elution buffer (0.2M glycine, 80mM HCl, pH 2) and incubated on ice for 5 minutes with the supernatant collected by centrifugation. Centrifugation speed was 1,000 3 g for 1 minute at 48C. Samples were resuspended in loading buffer and subjected to Western blotting.
Western Blot Analysis
Western blot analysis was performed on isolated brain capillaries from rats, and plasma and whole blood lysates from rats and humans. Plasma and whole blood were processed as described previously. 6, 18 Capillaries were isolated as described above and then lysed in buffer containing 1% NP-40, 150mM NaCl, 10mM Tris-HCl, 2mM EGTA, 50mM NaF, 1% phosphatase, and 1% protease inhibitors. The lysate was centrifuged at 17,000 3 g for 30 minutes. The supernatant was used for Western blotting. Primary antibodies against amylin (1:2,000, T-4157, Bachem-Peninsula Laboratories), occludin (1:300, 71-1500, Invitrogen), claudin-5 (1:1,000, 35-2500, Invitrogen), ZO-1 (1:300, 61-7300, Invitrogen), collagen IV (1:1,000, ab6586, Abcam), caveolin-1 (1:1,000, sc-894, Santa Cruz Biotechnology), and b-actin (1:10,000, PIMA515739, Fisher Scientific) were used in these analyses. Equal loading in Western blot experiments was verified by reprobing with a monoclonal anti-b-actin antibody (raised in mouse, clone BA3R, Thermo Fisher Scientific; 1:2,000). Protein levels were compared by densitometric analysis using ImageJ software.
Real-Time Quantitative Reverse Transcription Polymerase Chain Reaction
Expression levels of caveolin-1 and collagen IV in rat brain capillaries were measured using a protocol described previously. 29 Caveolin 
Cell Culture and Flow Cytometry Analysis
Prior to plating, culture flasks were coated with cell attachment factor solution (123-100, Sigma). Brain microvascular endothelial cells from WT adult Sprague-Dawley rats (RA-6023; Cell Biologics, Chicago, IL) were plated for 24 hours and used for experiments when they reached 70 to 90% confluency. Cells were incubated with 50lM human amylin (AS-60804; AnaSpec, Fremont, CA) for 2 hours at 378C. Cells were dissociated with trypsin and washed with cold PBS before being stained with propidium iodide (PI) and annexin V (AnV), according to manufacture protocol (V13241; Life Technologies, Waltham, MA). Apoptotic cells and necrotic cells were detected with analytical flow cytometer (LSRII; Becton Dickinson, Franklin Lakes, NJ).
Statistical Analysis
Parametric comparison of 2 groups was done using 2-tailed unpaired t test. Nonparametric comparison of 2 groups was done using Mann-Whitney unpaired t test. Two-way analysis of variance (ANOVA) with repeated measures followed by Bonferroni post hoc tests was used to analyze the Morris water maze data. Data are presented as mean 6 standard error of the mean. Difference between groups was considered significant when p < 0.05. All analyses were performed using GraphPad (La Jolla, CA) Prism 5.0 software.
Results

Impaired Neurological Functioning upon Inducing Amylin Dyshomeostasis in Rats
Both male and female HIP rats had increased plasma levels of amylin and developed overt hyperglycemia (>200mg/dl; nonfasted; Fig 1) . Western blot analysis of amylin in plasma samples showed multiple molecular weight bands (higher amylin immunoreactive signal was seen in HIP rats compared to WT rats). The higher molecular weight bands could correspond to circulating amylin aggregates, as suggested by previously published data, 18, 28, 49 or amylin binding to plasma components (including plasma APOE; see below). In contrast to WT littermate rats that had normal behavior, HIP rats had gait abnormalities and impaired balance (Supplementary Videos 1 and 2), spontaneous forelimb use, hindlimb clasping, and altered balance on a stationary inclined plane (see Fig 1) . HIP rats and WT controls had similar swim speeds; however, latency to platform over the 20 learning trials was longer for HIP rats compared to WT littermates (2-way ANOVA; p 5 0.03), indicating that HIP rats had impaired learning. Reference memory, defined as the latency to cross the platform at 24 hours after the second acquisition day (probe trial), was similar for HIP and WT rats, indicating no significant memory deficits associated with amylin dyshomeostasis once the task had been learned. Compared to males, female HIP rats developed hyperglycemia and neurologic deficits (see Supplementary Videos 1 and 2) later in life (ie, 12 months vs 18 months of age). Balance and gait abnormalities were milder in females compared to male HIP rats. 
Brain White Matter Injury in HIP Rats
Based on in vivo MRI (T 2 -weighted sequences), the brains of HIP rats had structural abnormalities, which were not present in control WT littermates (Fig 2) . Compared to controls, brains of diabetic male HIP rats showed areas of high T 2 signal in the lateral hippocampus and around the temporal horns of the lateral ventricles and expansion of the ventricles. Expansion of the ventricles and the high T 2 signal in the surrounding tissue may reflect defects in the resorption of cerebrospinal fluid or/and subcortical atrophy. Because the current MRI protocol only included coronal T 2 images, we cannot formally distinguish between these possibilities.
The volume of brain parenchyma was smaller in diabetic animals compared to controls (see Fig 2) . Injured ependyma and amylin deposition in choroid plexus were found in HIP rats with considerably enlarged ventricles.
The brains of rats with falls and impaired balance often revealed intracerebral hemorrhages (see Fig  2F, arrow) , which were not found in control WT littermates.
We used the fluorescent microsphere technique to assess the brain perfusion status in diabetic HIP rats relative to controls. The retrieval of fluorescent microspheres was lower in brain capillaries (but not parenchymal tissue) of HIP rats compared to controls (see Fig 2G) , suggesting brain hypoperfusion in HIP rats.
Immunohistochemical analysis of brain paraffin sections (corpus callosum, lateral ventricle area, thalamus, and hypothalamus) from diabetic rats showed parenchymal rarefaction. HIP rat brains had a loss of MBP immunoreactivity compared to brains from control animals (Fig 3A) . LFB stain of the white matter (see Fig  3B) showed the same degree of myelin loss in the brains of diabetic rats compared to controls. Vacuoles were found through the entire white matter in HIP rats in contrast to controls.
Cerebral Microhemorrhages and Perivascular Astrocyte Recruitment in HIP Rats
Histologic analysis of brain tissues from HIP rats showed microhemorrhages (Fig 4) . Serial staining of the periventricular region with the amylin antibody showed amylin deposits in microvessels and perivascular areas. Vascular amylin deposition coincided with white matter vacuolation. At higher magnification, the same brain area stained with H&E showed loss of cellular details and erythrocytes around a blood vessel. Amylin was present within the vessel wall and was associated with enlarged Virchow-Robin spaces. In contrast, tissue sections from similar levels of the brain from a WT animal had no vascular or tissue abnormalities. Staining for GFAP revealed robust recruitment of astrocytes in areas of vascular tissue damage, whereas sections taken at a similar level of the hypothalamus from a control animal lacked obvious abnormalities, including no astrocytosis near intact microvessels. Amylin deposition was also found in association with infarction cores and disrupted vessel walls. Amylin deposition was also present in hippocampal capillaries of HIP rats.
Cerebral Microhemorrhages and Perivascular Astrocyte Recruitment following Intravenous Infusion of Aggregated Amylin in AKO Rats
HIP rats had elevated circulating levels of aggregated amylin (see Fig 1A) . To test whether circulating aggregated amylin injures the endothelium independently of glucotoxicity, we generated rats with deleted amylin gene (AKO rats; Fig 5) . AKO rats were intravenously infused with aggregated human amylin (2lg/g body weight, every day [q.d.] for 7 days; approximately 3 orders of magnitude higher than the physiological level of amylin in HIP rats). Western blot analysis of blood lysates from amylin-infused AKO rats, HIP rats, and humans with type 2 diabetes showed similar distributions of amylinpositive molecular complexes. Infusion of aggregated amylin provoked accumulation of amylin in the brain microvessels, astrocyte recruitment in areas of vascular injury, and brain microhemorrhages; however, the white matter in amylin-injected animals was intact as assessed by in vivo MRI.
Vascular Amylin Deposition Is Modulated by the Amylin-APOE Interaction
To test for a possible interaction of amylin with APOE in vivo, AKO rats (which express rat APOE, but lack amylin) were intravenously infused with combined aggregated human amylin (2lg/g body weight) and APOE4 (1.2lg/g body weight), or only aggregated human amylin for 7 days (q.d.). Western blot analysis of plasma samples from rats in the 2 groups showed greater amylin binding to APOE4 compared to the endogenous rat APOE (Fig  6A) , consistent with previous ex vivo data demonstrating that APOE4 modulates amylin aggregation. 22 To further test the interaction of amylin with plasma APOE, plasma samples from HIP rats were enriched in APOE by Western blot analysis of pancreatic tissues demonstrating that the protein level of amylin is reduced in the AKO rats compared to WT littermates. (E) Cropped Western blot of amylin in blood lysates from amylin-infused AKO rats, HIP rats, and type 2 diabetes (T2D) patients. The amylin band at 10kDa (the amylin dimer) required longer exposure time and is displayed separately. Experiments are repeated twice. (F, G) Representative images of immunohistochemical staining with amylin (F) and costaining for amylin (brown) and glial fibrillary acidic protein (GFAP; green; G) in the cerebral cortex of an amylin-infused AKO rat versus an age-matched AKO rat without amylin infusion (n 5 3). (H) Prussian blue dye in the brain cortex area of an amylin-infused AKO rat versus an age-matched AKO rat without amylin infusion. Analysis of the number of brain microhemorrhages in amylin-infused (inf.) AKO and control AKO rats (n 5 6) is shown. (I) Three slices (1, 3, and 5 of 7 consecutive slices 1mm apart) of coronal T 2 -weighted magnetic resonance images comparing the brain in an AKO rat before and after infusion with aggregated human amylin (2lg/g body weight, every day, 7 days; n 5 3). GAPDH 5 glyceraldehyde-3-phosphate dehydrogenase; HET 5 heterozygous; KO 5 knockout.
immunoprecipitation and were analyzed by Western blot with an antiamylin antibody. Figure 6B depicts amylin that formed molecular complexes with plasma APOE in HIP rats. Not surprisingly, amylin bound to other plasma apolipoproteins, as indicated by the immunoreactivity signal of amylin in APOA-I enriched by immunoprecipitation. Because amylin appears to bind to APOE4 in vivo, we hypothesized that infusion of APOE4 would exacerbate systemic amylin dyshomeostasis and cerebral vascular injury in HIP rats (see Fig 6) . To test this hypothesis, HIP rats were intravenously infused with APOE4 (1.2lg/ g body weight, q.d., for 7 days). The infusion of APOE4 enhanced amylin accumulation in the brains of HIP rats. Figure 6D depicts leakage of amylin from a brain microvessel of an HIP rat that was infused with APOE4. No obvious extravasation of APOE4 was present in the APOE4-infused HIP rats.
Shared Feature of Amylin Vasculopathy in
Brains of HIP Rats, Human Amylin-Infused AKO Rats, and Humans with Dementia and Type 2 Diabetes Immunohistochemical analysis with an amylin antibody of brain tissues from patients with type 2 diabetes and dementia showed vascular changes associated with amylin deposition. Figure 7A , B displays sections from the brain of a 93-year-old man (APOE 4/4 carrier with type 2 diabetes and CERAD definite Alzheimer disease [AD], Braak stage V, and CAA severity 2). The vascular histopathology includes amylin deposits in the smooth muscle layer of arterioles and distortion of the amylin-positive vascular wall contours in capillaries. Figure 7C shows a brain section from a 92-year-old woman with type 2 diabetes and unknown APOE genotype (CERAD definite AD, Braak stage V, and CAA severity 3). Amylin deposition was found in association with disruption of the vessel wall. Figure 7D is from the brain of another man (91 years old, APOE 3,4 carrier, CERAD definite AD, Braak stage V, but no CAA). Amylin immunoreactivity signal was detected in an area corresponding to a chronic infarct. In the brain that is displayed in Figure  7A , amylin is colocalized with perivascular reactive astrocyte recruitment in disrupted blood vessel walls. Reactive astrocytosis was lower around blood vessels of aged control individuals, with the caveat of the limited sample size. These pathologic changes were not present in the brain blood vessels of healthy aged individuals. Figure 7F provides a representative section from the 3 brains investigated in this study. Immunoconfocal microscopy analysis of amylin and collagen IV, a component of the basement membrane structure of the blood vessels, in the brain tissue from the 91-year-old patient described above showed amylin deposition in an arteriole and a presumed capillary profile. Brain microvessels of HIP rats and AKO rats that were intravenously infused with aggregated human amylin had similar amylin deposits as in dementia patients who also had type 2 diabetes. In contrast, brain sections from a WT rat showed no amylin staining in brain blood vessels.
Vascular Amylin Deposition Injures Endothelial Cells and Degrades Tight Junction Components
To assess the impact of aggregated amylin on the endothelium, cerebral capillaries were isolated from HIP and WT rat brains and stained for amylin and caveolin-1, a protein that is abundant in endothelial cells. Areas of amylin deposition (green) showed weak immunoreactive caveolin signal, suggesting the loss of endothelial cells (Fig 8) . Consistent with immunoconfocal data, Western blot analysis demonstrated depletion of caveolin and collagen in brain capillary lysates from HIP rats compared
to WT littermates. There was similar depletion of collagen and caveolin-1 in human amylin-infused AKO rats. The transcript levels for caveolin-1 and collagen IV were unchanged, suggesting that the loss of capillary stability was associated with degradation of basement membrane structure and endothelium.
A flow cytometry analysis of cultured brain microvascular endothelial cells from rats was performed to test the viability of endothelial cells after exposure to aggregated human amylin. The interaction of aggregated human amylin with endothelial cells resulted in a significant increase of both early apoptotic (AnV Fig  8D) .
The tight junction components, claudin, occludin, and ZO adapter proteins were degraded in cerebral capillaries from HIP rats (see Fig 8E) . There was some reduction in tight junction components in amylininfused AKO rats. Thus, microhemorrhages and amylin vasculopathy in HIP rat brains were associated with endothelial damage.
Discussion
Our data suggest that the amyloidogenicity of the human amylin peptide, amylin hypersecretion, and plasma APOE are important mediators of amylin deposition in the cerebral microvasculature. Vascular amylin deposition was associated with endothelial cell damage and degradation of tight junctions, which could explain the associated microhemorrhages and recruitment of perivascular astrocytes that occurred in HIP rats and in AKO rats infused with aggregated human amylin. Accumulated injury to cerebral small vessels can contribute to hypoperfusion, leading to injury of brain parenchyma, loss of brain volume, and neurologic deficits (as seen in HIP rats; see proposed mechanism in Fig 8F) . Our findings are consistent with previous reports that implicated amylin dyshomeostasis as a contributor to the development of type 2 diabetes 9, 15, 16, [25] [26] [27] and cardiovascular disease. [17] [18] [19] The most important finding of this study is the demonstration of amylin-provoked microhemorrhages in HIP rats and AKO rats infused with aggregated human amylin. This provides direct evidence that diabetes-associated amylin dyshomeostasis provokes a microangiopathy. This is a noteworthy finding because amylin deposits are present in the brain microvessels of patients with type 2 diabetes and dementia. Cerebral microhemorrhages occur frequently in patients with both ischemic and hemorrhagic stroke 50 and in individuals with CAA. 4 In contrast to CAA, brain microvessels in AKO rats infused with aggregated human amylin showed concentric amylin deposition, indicating that circulating aggregated amylin results in luminal amylin deposition. Thus, amylin-mediated narrowing of brain microvessels is a likely contributor to brain hypoperfusion and parenchymal loss, leading to impaired neurological functioning in diabetic HIP rats. Cerebral microvascular injury that occurs in patients with type 2 diabetes is suggested to result from nonenzymatic glycation of proteins and subsequent production of toxic derivatives that induce endothelial cell oxidative damage. 32, 33 The induction of cerebral microhemorrhages and surrounding neuropil injury occurred in amylin-infused AKO rats in the absence of hyperglycemia, which suggests that circulating aggregated amylin is a pathologic substrate for endothelial dysfunction in the setting of diabetes. Further study is required to establish a causal link between the level of circulating amylin and the effect of the resulting microvascular injury on brain parenchyma and functional outcomes in humans. The cellular and molecular mechanisms that underlie the impact of cerebral microvascular injury on neural circuit function are complex and incompletely understood. This limitation stems in part from a paucity of experimental models. 51, 52 In HIP rats, neurological . (E) Cropped Western blot of endothelial cell tight junction proteins (ZO-1, occludin, and claudin-5) in capillary lysates from HIP and WT brain (n 5 5; left panel), and amylin-infused AKO and control AKO rats (n 5 3; right panel). Corresponding densitometry analyses of tight junction protein levels are displayed in the lower panel. (F) Proposed mechanism: aggregated amylin causes endothelial dysfunction and microvascular injury and is modulated by amylin transport in the brain via plasma apolipoprotein E4 (APOE4). Error bars represent mean 6 standard error of the mean; *p < 0.05, **p < 0.01, ***p < 0.001, n.s. 5 not significant by unpaired 2-tailed Student t test.
deficits are associated with white matter injury caused by vascular amylin deposition. The present results indicate that expressing human amylin in species that do not develop type 2 diabetes (ie, mice and rats) can provide a means to better understand the complex vascular factors affecting white matter integrity in patients with diabetes and dementia.
APOE is a plasma protein that serves as a ligand for low-density lipoprotein receptors, participates in the transport of cholesterol and other lipids among various cells of the body, 53 and is present in amylin amyloidcontaining pancreatic tissue from humans. 23, 24 The infusion of APOE4 exacerbated amylin-mediated capillary injury and brain amylin accumulation in HIP rats. The result suggests an interaction between amylin and plasma APOE as a potential mechanism underlying brain amylin pathology. Because APOE4 may modulate amylin aggregation, 22 we speculate that elevated levels of plasma APOE4 could trigger the formation of toxic amylin aggregates in the blood. Additional studies are needed to elucidate the potential role of APOE alleles in promoting vascular amylin deposition. Amylin plays a complex role in modulating the peripheral energy balance. [11] [12] [13] [14] We demonstrated that systemic amylin dyshomeostasis contributes to microvascular injury in the setting of diabetes. Thus, amylin dyshomeostasis may be a therapeutic target in diabetesassociated stroke and dementia.
